PMID- 30284706
OWN - NLM
STAT- MEDLINE
DCOM- 20190919
LR  - 20190919
IS  - 1776-260X (Electronic)
IS  - 1776-2596 (Linking)
VI  - 13
IP  - 5
DP  - 2018 Oct
TI  - EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung 
      Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).
PG  - 621-629
LID - 10.1007/s11523-018-0594-x [doi]
AB  - BACKGROUND: Non-small cell lung cancer (NSCLC) has a 5-year survival of 5-16%. 
      Epidermal growth factor receptor (EGFR) mutations, in most cases, confer 
      sensitivity to EGFR tyrosine kinase inhibitor (TKI) therapy. Nonetheless, it is 
      still unclear why clinical outcomes vary among patients with identical EGFR 
      mutations. The amplification of the EGFR gene (EGFRamp) may play a significant 
      role. OBJECTIVE: Compare the complete (CR) and partial response (PR) rates, 
      overall survival (OS), and progression-free survival (PFS) in Hispanic patients 
      with lung adenocarcinoma treated with erlotinib with EGFR mutations (L858R or 
      exon 19 deletion [Del19]) with and without concomitant EGFRamp. PATIENTS AND 
      METHODS: Seventy-two EGFR-positive lung adenocarcinoma patients of Hispanic 
      origin, who underwent first-line treatment with erlotinib, were evaluated for 
      EGFRamp by fluorescence in situ hybridization (FISH). The clinical outcomes were 
      analyzed according to EGFR mutations and EGFRamp status. RESULTS: 30.6% of 
      samples showed EGFRamp, more frequently present in patients with Del19 
      (p = 0.05). Patients with EGFRamp had a longer PFS (in months) [(28.5, 95% CI 
      22.3-34.6) vs. (11.0, 95% CI 8.2-16.7); p = 0.002] and OS [(37.8, 95% CI 
      30.9-44.7) vs. (27.1, 95% CI 12.8-41.3); p = 0.009] than those without. EGFRamp 
      significantly influenced the response to erlotinib (p = 0.0001). EGFRamp+/Del19 
      had a longer OS, 37.8 (95% CI 31.0-44.6), compared to EGFRamp+/L8585R, 27.5 (95% 
      CI 12.4-42.5) (p < 0.001) and longer PFS (p = 0.043). CONCLUSION: Among Hispanic 
      patients, EGFRamp was present in 30% of patients with EGFR mutations. EGFR 
      mutations and EGFRamp are associated with better OS, PFS, CR, and PR to erlotinib 
      and, hence, could aid in the correct selection of patients that benefit from EGFR 
      TKI treatment.
FAU - Ruiz-Patino, Alejandro
AU  - Ruiz-Patino A
AD  - Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, 
      c. 318, Bogota, Colombia.
FAU - Castro, Christian David
AU  - Castro CD
AD  - Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, 
      c. 318, Bogota, Colombia.
FAU - Ricaurte, Luisa Maria
AU  - Ricaurte LM
AD  - Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, 
      c. 318, Bogota, Colombia.
FAU - Cardona, Andres F
AU  - Cardona AF
AUID- ORCID: 0000-0003-3525-4126
AD  - Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, 
      c. 318, Bogota, Colombia. andres.cardona@clinicadelcountry.com.
AD  - Clinical and Translational Oncology Group, Institute of Oncology, Clinica del 
      Country, Bogota, Colombia. andres.cardona@clinicadelcountry.com.
AD  - Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad El 
      Bosque, Bogota, Colombia. andres.cardona@clinicadelcountry.com.
FAU - Rojas, Leonardo
AU  - Rojas L
AD  - Clinical and Translational Oncology Group, Institute of Oncology, Clinica del 
      Country, Bogota, Colombia.
AD  - Clinical Oncology Department, Clinica Colsanitas, Bogota, Colombia.
FAU - Zatarain-Barron, Zyanya Lucia
AU  - Zatarain-Barron ZL
AD  - Thoracic Oncology Unit and Laboratory of Personalized Medicine, Instituto 
      Nacional de Cancerologia (INCan), Mexico City, Mexico.
FAU - Wills, Beatriz
AU  - Wills B
AD  - Internal Medicine Department, Johns Hopkins University, Baltimore, MD, USA.
FAU - Reguart, Noemi
AU  - Reguart N
AD  - Medical Oncology Department, Hospital Clinic, Barcelona, Spain.
FAU - Carranza, Hernan
AU  - Carranza H
AD  - Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, 
      c. 318, Bogota, Colombia.
AD  - Clinical and Translational Oncology Group, Institute of Oncology, Clinica del 
      Country, Bogota, Colombia.
FAU - Vargas, Carlos
AU  - Vargas C
AD  - Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, 
      c. 318, Bogota, Colombia.
AD  - Clinical and Translational Oncology Group, Institute of Oncology, Clinica del 
      Country, Bogota, Colombia.
FAU - Otero, Jorge
AU  - Otero J
AD  - Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, 
      c. 318, Bogota, Colombia.
AD  - Clinical and Translational Oncology Group, Institute of Oncology, Clinica del 
      Country, Bogota, Colombia.
FAU - Corrales, Luis
AU  - Corrales L
AD  - Clinical Oncology Department, Hospital San Juan de Dios, San Jose, Costa Rica.
FAU - Martin, Claudio
AU  - Martin C
AD  - Thoracic Oncology Unit, Alexander Fleming Institute, Buenos Aires, Argentina.
FAU - Archila, Pilar
AU  - Archila P
AD  - Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, 
      c. 318, Bogota, Colombia.
FAU - Rodriguez, July
AU  - Rodriguez J
AD  - Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, 
      c. 318, Bogota, Colombia.
FAU - Avila, Jenny
AU  - Avila J
AD  - Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, 
      c. 318, Bogota, Colombia.
FAU - Bravo, Melissa
AU  - Bravo M
AD  - Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, 
      c. 318, Bogota, Colombia.
FAU - Pino, Luis Eduardo
AU  - Pino LE
AD  - Medical Oncology Group, Fundacion Santa Fe de Bogota, Bogota, Colombia.
FAU - Rosell, Rafael
AU  - Rosell R
AD  - Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, 
      Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
FAU - Arrieta, Oscar
AU  - Arrieta O
AD  - Thoracic Oncology Unit and Laboratory of Personalized Medicine, Instituto 
      Nacional de Cancerologia (INCan), Mexico City, Mexico.
CN  - Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Target Oncol
JT  - Targeted oncology
JID - 101270595
RN  - 0 (Antineoplastic Agents)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adenocarcinoma of Lung/*drug therapy/enzymology/genetics/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*therapeutic use
MH  - ErbB Receptors/antagonists & inhibitors/genetics
MH  - Erlotinib Hydrochloride/*therapeutic use
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/enzymology/genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Survival Analysis
MH  - Young Adult
EDAT- 2018/10/05 06:00
MHDA- 2019/09/20 06:00
CRDT- 2018/10/05 06:00
PHST- 2018/10/05 06:00 [pubmed]
PHST- 2019/09/20 06:00 [medline]
PHST- 2018/10/05 06:00 [entrez]
AID - 10.1007/s11523-018-0594-x [pii]
AID - 10.1007/s11523-018-0594-x [doi]
PST - ppublish
SO  - Target Oncol. 2018 Oct;13(5):621-629. doi: 10.1007/s11523-018-0594-x.